OncologyImmuno-oncologyImmunology & inflammation PopPK

Envafolimab subcutaneous population PK

Reference paper ↗

A subcutaneous population PK model representing envafolimab absorption, systemic concentration, renal-function covariates, and time-varying clearance.

Therapeutic
Envafolimab
Modality
Monoclonal antibody
Target
PD-L1 / CD274
Disease
PD-L1-positive solid tumors
Model type
PopPK

Complete model workspace

Checking workspace access…

Parameters
9
States
4
Equations
4
Derived outputs
11

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Final model 150 mg QW for 20 weeks

How do dosing interval, renal function, and time-varying clearance change envafolimab exposure? Explore this intervention regimen through Envafolimab concentration, Cumulative envafolimab exposure, Individual clearance, Absorption rate.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–140 day; step 0.25

InputDefaultAvailable range
Absorption rate constant0.0147 1/hr0.00735–0.02205 1/hr
Typical clearance0.0478 L/hr0.0239–0.0717 L/hr
Apparent distribution volume15.5 L7.75–23.25 L
Time to half-maximal change34 day17–51 day
Creatinine clearance95.14 mL/min47.57–142.7 mL/min

Expected readouts

Envafolimab concentration · Exposure (AUC) (mg*day/L) · Individual clearance · Absorption rate constant

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 9 declared model parameters.

More key parameters (1)

How the model represents the biology

A subcutaneous population PK model representing envafolimab absorption, systemic concentration, renal-function covariates, and time-varying clearance.

How do subcutaneous absorption and time-varying clearance shape envafolimab exposure?A subcutaneous envafolimab dose enters a depot, is absorbed into central systemic exposure, and undergoes clearance modulated by renal function, elapsed time, and a country factor. Central concentration accumulates as exposure.BIOLOGY OVERVIEWHow do subcutaneous absorption and time-varying clearance shape envafolimabexposure?Subcutaneous doseEnvafolimab inputSC depotFirst-order absorptionSystemic exposureCentral envafolimab amountClearance driversRenal function, time, countryTime-varying clearanceCentral concentration lossCumulative exposureCentral concentration integralPRIMARY READOUTSEnvafolimab concentrationEnvafolimab concentrationCumulative exposureCumulative exposureIndividual clearanceIndividual clearanceAbsorption rateAbsorption rate

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: PD-L1 binding or occupancy, tumor immunity, efficacy, peripheral distribution, and target-mediated disposition are not represented.

Modeled relationships (5)
  • Subcutaneous dose → SC depot: SC input (flow)
  • SC depot → Systemic exposure: absorption (flow)
  • Systemic exposure → Time-varying clearance: CL(t) (loss)
  • Clearance drivers → Time-varying clearance: modifies CL (modulation)
  • Systemic exposure → Cumulative exposure: integrates C (production)

Modeled relationships: Subcutaneous dose to SC depot: SC input (flow); SC depot to Systemic exposure: absorption (flow); Systemic exposure to Time-varying clearance: CL(t) (loss); Clearance drivers to Time-varying clearance: modifies CL (modulation); Systemic exposure to Cumulative exposure: integrates C (production).

Primary readouts: Envafolimab concentration; Cumulative exposure; Individual clearance; Absorption rate.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID cui_2024_envafolimab_sc_pdl1_midd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics